Aravive Inc.

11/20/2019 | Press release | Distributed by Public on 11/20/2019 06:03

Aravive Reports Positive Data Supporting Relationship Between AVB-500 Levels, Anti-Tumor Activity and Progression Free Survival in Women with Ovarian Cancer